Semax Half-Life and Pharmacokinetics: What Studies Report

What the searched question asks, and what the literature actually covers

"Semax half-life" is one of the most common peptide search queries, and it is also one of the hardest to answer from indexed primary literature. A half-life value belongs to a pharmacokinetic study: an experiment that samples plasma, cerebrospinal fluid or tissue at multiple time points after a single administration, quantifies the compound with an analytical method such as mass spectrometry or a radiolabel, and fits a concentration-time curve. The papers verified for this page are not that kind of study. They are pharmacodynamic and mechanistic experiments in rodents that asked what Semax did to gene transcription, monoamine systems, behaviour, blood coagulation or tissue morphology — not how quickly it appeared in and disappeared from the circulation.

That distinction matters, because the two are routinely confused. A peptide can produce measurable downstream effects hours or days after the parent molecule is undetectable, because the effects run through transcription, protein synthesis and network changes rather than through continuous receptor occupancy. Several of the verified studies illustrate exactly that layered timescale, and they are described below. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a specific health situation or compound.

Pharmacokinetic vocabulary, defined

Understanding why the verified literature cannot supply a half-life requires the standard terms:

• Absorption — the fraction and rate at which a compound enters systemic circulation from the administration site. For intranasal peptides, this can include both nasal mucosal uptake and possible direct nose-to-brain transfer.
• Bioavailability (F) — the proportion of an administered amount reaching circulation unchanged, referenced against intravenous administration.
• C_max and T_max — peak measured concentration and the time at which it occurred.
• Distribution (V_d) — the apparent volume into which the compound spreads, including whether it reaches central nervous system tissue.
• Metabolism — enzymatic breakdown. For short peptides this is dominated by exopeptidases and endopeptidases in plasma, mucosa, liver and brain tissue rather than by cytochrome P450 pathways.
• Elimination half-life (t½) — the time for the measured concentration to fall by half during the terminal elimination phase.
• Clearance (CL) — the volume of plasma cleared of the compound per unit time.

None of these parameters were reported as numerical values in the studies verified for this page. Any specific half-life figure circulating in forums, vendor copy or AI summaries should be treated as unsourced until a reader can trace it to a primary pharmacokinetic paper with a stated species, route, dose and assay.

What Semax is, structurally

Semax is described in the peer-reviewed literature as a synthetic analogue of the adrenocorticotropic hormone fragment ACTH(4-10); a 2021 rat study used that exact framing when it examined the peptide's effects after early-life fluvoxamine exposure (PMID 33418449). Other papers name the molecule by its composition as an ACTH(4-7) fragment extended with a C-terminal Pro-Gly-Pro tripeptide, as in a 2017 study of hepatocyte morphofunctional state under chronic stress (PMID 28577097). That structural detail is relevant to pharmacokinetic reasoning: the Pro-Gly-Pro moiety is itself a biologically studied fragment, and a 2010 rat ischemia study examined Semax and Pro-Gly-Pro as separate treatments, reporting that both influenced the transcription of neurotrophins and their receptor genes (PMID 19633950). Researchers therefore have at least one published reason to consider whether fragment-level activity contributes to observed effects — but that paper measured transcription, not peptide concentrations, so it cannot be read as metabolite pharmacokinetics.

Species, routes and models in the verified set

The table below summarises what the verified papers studied and what pharmacokinetic information they contributed. The consistent entry in the final column is the central finding of this page.

Absorption: what was and was not established

No verified paper on this page reported an absorption rate, a bioavailability percentage or a nasal-versus-parenteral comparison for Semax. Route information in these abstracts, where present at all, is incidental to the experimental design rather than the object of study. That means a reader cannot derive from this evidence base how much of an administered amount reached circulation, how fast it did so, or whether one route produced higher exposure than another.

This is a genuine gap rather than a summarising choice. Peptide absorption is highly formulation-dependent — pH, excipients, mucosal residence time and peptidase activity at the administration site all change the outcome — so absorption figures cannot be borrowed from a different peptide or a different formulation and applied to Semax.

Distribution: indirect evidence from central effects

The strongest pharmacokinetic inference available from the verified set is indirect: several studies reported biological changes in central nervous system tissue after systemic or peripheral administration, which implies that either the peptide, a fragment, or a downstream signal reached the target tissue. A 2010 rat study reported changes in neurotrophin and neurotrophin-receptor gene transcription in brain tissue after cerebral ischemia (PMID 19633950), and a 2020 study reported transcriptome-level changes following cerebral ischaemia-reperfusion in rats (PMID 32580520). A 2005 rodent study reported activation of dopaminergic and serotoninergic brain systems (PMID 16362768), and a 2025 mouse study reported regulation of the μ opioid receptor gene Oprm1 with deubiquitination and functional recovery after spinal cord injury in female mice (PMID 40692165).

Central effects are consistent with central exposure, but they are not a measurement of it. None of these papers reported brain-to-plasma ratios, tissue concentrations, or a time course of peptide presence in CNS tissue. Whether the observed changes reflected the intact peptide crossing into brain tissue, a metabolite doing so, or a peripherally initiated signalling cascade is not resolved by the evidence verified here.

Half-life versus duration of effect

Readers looking for a half-life are often actually asking about duration of effect, and the verified literature speaks to that second question in a limited way — through repeated-administration designs rather than single-dose kinetics. A 2021 study examined behavioural and neurochemical alterations in white rats in a model of early-life fluvoxamine exposure, reporting attenuation of those alterations (PMID 33418449). A 2017 study examined hepatocyte morphofunctional state in a chronic emotional and painful stress model (PMID 28577097), and a 2025 paper examined Semax and a derivative in an animal model of Alzheimer's disease (PMID 41479572).

Transcriptional and network-level outcomes of this type unfold over hours to weeks and are, by construction, decoupled from plasma persistence. A 2020 functional connectomic analysis of Selank and Semax approached the question at the level of brain network organisation rather than molecule concentration (PMID 32342318). So an effect measured at day 7 of an experiment tells a reader nothing about t½, and a short t½ would not rule out a durable effect.

Metabolism and clearance: not characterised in the verified set

No verified paper reported metabolite identification, metabolic stability in plasma or brain homogenate, renal or hepatic clearance, or excretion balance for Semax. The closest adjacent data point is the parallel testing of Pro-Gly-Pro alongside Semax in the 2010 ischemia transcription study (PMID 19633950), which established that the fragment was itself biologically active in that model but did not establish that it was a measured metabolite of the parent peptide in vivo.

Human pharmacokinetic data: absent from the verified evidence

Every paper verified for this page was an animal or preclinical study in rats, mice or unspecified rodents. None were human trials, and none reported human plasma concentrations, human half-life, human bioavailability or human clearance. On the regulatory side, Semax is not an FDA-approved drug in the United States; material sold under the name in Western markets is typically labelled for research use only. Where Semax appears in national drug registers outside the United States, registration documentation is not equivalent to an indexed peer-reviewed pharmacokinetic study and should not be cited as one.

The practical consequence for anyone evaluating online claims: a stated half-life "in humans" that cannot be traced to a published human study is an unverified number, regardless of how confidently it is repeated or how often it is copied between sites.

Systemic Signals in Animal Studies: What Studies Report

Two verified papers reported outcomes outside the nervous system that are relevant to how researchers think about systemic exposure. A 2010 study reported anticoagulation and antiplatelet effects of Semax under conditions of acute and chronic immobilisation stress (PMID 21113455). A 2017 study reported effects on the morphofunctional state of hepatocytes in a chronic emotional and painful stress model (PMID 28577097).

These are findings in stressed animal models, reported as measured endpoints rather than as characterisations of human safety. Neither paper reported a concentration-effect relationship, so the results cannot be mapped onto exposure windows or onto any assumption about how long a systemic effect would persist relative to plasma levels.

How to read a PK claim about Semax

1. Ask for the species and route. A half-life in rats after intraperitoneal injection is not a half-life in humans after intranasal administration.
2. Ask for the assay. Peptide quantification requires a validated analytical method; without one, a number has no provenance.
3. Separate kinetics from dynamics. Gene-expression and behavioural studies, which dominate the Semax literature verified here, are dynamic endpoints.
4. Check for the primary source. Many widely repeated peptide half-life figures resolve, on tracing, to secondary summaries citing other secondary summaries.
5. Treat gaps as gaps. The honest reading of the verified set is that Semax pharmacokinetics, particularly in humans, remain uncharacterised in the literature reviewed on this page.

References

• Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (British Journal of Pharmacology, 2025)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Neuropeptides, 2021)
• The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (Acta Naturae, 2025)
• Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia (Cellular and Molecular Neurobiology, 2010)
• Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress (Bulletin of Experimental Biology and Medicine, 2010)
• Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex (Bulletin of Experimental Biology and Medicine, 2006)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats (Genes, 2020)
• Semax prevents learning and memory inhibition by heavy metals (Doklady Biological Sciences, 2016)
• Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (Neurochemical Research, 2005)